AOD-9604: The Fat Loss Fragment Protocol

Category: Protocols Type: Protocol Read Time: 14 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/aod-9604-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol.

Overview

AOD-9604 — short for "Anti-Obesity Drug 9604" — is a modified fragment of the C-terminus of human growth hormone (hGH). Specifically, it is built from residues 177–191 of the hGH molecule, with an added tyrosine residue and a stabilizing disulfide bond that distinguish it from the closely related Fragment 176-191.

Developed in the late 1990s and early 2000s by Metabolic Pharmaceuticals in Australia, AOD-9604 was designed with a single goal in mind: isolate the fat-burning region of growth hormone while removing the growth-promoting, IGF-1-elevating, and glucose-disturbing effects of full hGH.

Key Properties

• Modified hGH C-terminus fragment (residues 177–191 + Tyr + disulfide bridge)
• Originally pursued as an oral anti-obesity drug candidate
• Does not raise IGF-1
• Does not appear to affect blood glucose or insulin sensitivity
• Holds GRAS (Generally Recognized As Safe) status in the U.S. as a research/nutraceutical compound — but is not FDA-approved as a drug for weight loss

AOD-9604 is sometimes marketed as a "lipolytic peptide" by compounding pharmacies and research suppliers. The actual clinical record is more measured than the marketing suggests — a theme we'll return to throughout this guide.

Mechanism of Action

AOD-9604 is theorized to mimic the fat-metabolism signaling region of full hGH without engaging the growth and metabolic pathways tied to the rest of the molecule.

Proposed pathways:

1. Beta-3 adrenergic receptor (β3-AR) signaling — Preclinical research suggests AOD-9604 may upregulate β3-AR activity in adipose tissue, which is the primary "fat-burning" receptor in human white and brown fat.
2. Stimulation of lipolysis — Promotes the breakdown of triglycerides stored in adipocytes into free fatty acids that can be oxidized for energy.
3. Inhibition of lipogenesis — May reduce the conversion of non-fatty food materials into body fat.
4. No effect on IGF-1 — Unlike full hGH or true secretagogues (CJC-1295, ipamorelin, MK-677), AOD-9604 does not appear to raise IGF-1 levels in human trials.
5. No measurable effect on glucose tolerance or insulin sensitivity — A key differentiator from full GH therapy, which can be diabetogenic.

Important nuance: Much of the β3-AR mechanism comes from rodent models. Human β3-AR biology differs meaningfully from mouse biology, and this is one reason translation of AOD-9604 results from mice to humans has been less impressive than early marketing claimed.

AOD-9604 vs Fragment 176-191

This is one of the most confused comparisons in the peptide world. Both compounds are derived from the same region of hGH and are marketed in overlapping ways — but they are not identical molecules.

Sourcing concerns

Independent third-party testing of "AOD-9604" vials sold in the gray market has, on multiple occasions, returned results inconsistent with the labeled molecule. Some vials test as Fragment 176-191. Some test as inert peptide mass. A few have tested as something else entirely.

Practical implication: Always demand a third-party COA, and recognize that even with a COA, supply-chain integrity for these niche fragments is weaker than for more popular peptides like BPC-157 or CJC-1295.

Dosing Protocols

There is no FDA-approved dose. The protocols below reflect what has been used in clinical trials and what is commonly used in compounding pharmacy and research contexts.

Notes on each route

• Subcutaneous injection is the most predictable route. The molecule reaches systemic circulation reliably, and dosing is straightforward.
• Sublingual troches are increasingly common via compounding pharmacies. Bioavailability of peptides through buccal/sublingual tissue is not well-characterized for AOD-9604 specifically, and the dose is typically 2–4× the injectable dose to compensate.
• Oral capsules were the original Metabolic Pharmaceuticals goal. Real-world bioavailability remains uncertain and likely low.

Weight-based dosing

Clinical trial dosing has ranged from approximately 1 mg to 30 mg orally, and roughly 250–500 mcg subcutaneously in non-trial use. There is no validated weight-based formula — most users dose flat.

Fasted vs Fed Timing

AOD-9604 protocols typically call for AM fasted dosing. The rationale:

1. Lipolysis is most readily stimulated in a low-insulin state. Insulin is anti-lipolytic. Dosing before breakfast keeps insulin low and theoretically allows fat mobilization signaling to dominate.
2. Mirrors GH physiology. The body's natural GH pulses are largest during sleep and in the early morning, in a fasted state.
3. Pairs well with fasted cardio. Many users dose AOD-9604, wait 30–60 minutes, and perform low-intensity steady-state cardio to oxidize the freed fatty acids.

Practical AM protocol

• Wake up
• Inject 250–500 mcg subcutaneously (abdomen)
• Wait 30–45 minutes (black coffee/water only)
• Optional: 30–45 minutes low-intensity cardio
• Then eat first meal

Some users also dose a second time pre-workout in the late afternoon — also fasted from food for ~2 hours prior. This is anecdotal and not supported by trial data.

Expected Outcomes

This is where we have to be honest about what the data shows.

Realistic timeline

• Weeks 1–4: No visible change. Some users report a subjective sense of "easier" fat mobilization or appetite suppression. Most report nothing.
• Weeks 4–8: Possible mild reduction in subcutaneous fat, particularly in the abdomen and waist, in users who are also in a caloric deficit.
• Weeks 8–12: Gradual changes most evident at this point. Effects are modest compared to caloric/training interventions.

What the trials showed

Metabolic Pharmaceuticals' Phase IIb and Phase III trials in obese populations are widely cited. The honest summary: AOD-9604 was generally safe, but the weight loss outcomes did not consistently reach clinical significance over placebo at the doses tested. The development program for an approved obesity drug was eventually discontinued.

This is a critical fact often omitted from supplier marketing.

What it is not

• Not a substitute for caloric deficit
• Not a substitute for resistance training
• Not a rapid-fat-loss compound on the scale of GLP-1 receptor agonists like semaglutide or tirzepatide
• Not a body-recomposition agent in the way many users hope

Side Effects & Safety

In trials, AOD-9604 had one of the cleaner safety profiles in the peptide space.

Commonly reported

• Injection site reactions (redness, mild swelling)
• Mild headache, especially in first week
• Occasional dizziness or lightheadedness (uncommon)

Not observed in trials

• No significant IGF-1 elevation
• No impact on fasting glucose or HbA1c
• No cardiovascular signal
• No clear suppression of endogenous GH

Theoretical considerations

• Pregnancy/breastfeeding: avoid
• Active malignancy: discuss with oncologist (general caution applies to anything that signals through growth pathways, even though AOD-9604 does not raise IGF-1)
• Children/adolescents: not studied

Stacking

AOD-9604 is almost never the "main lever" in a fat loss protocol. It is most useful as a mild adjunct to fundamentals.

Foundation (non-negotiable)

• Caloric deficit of 300–500 kcal/day
• Resistance training 3–5x/week
• Protein at 0.8–1.0 g/lb bodyweight
• Sleep 7+ hours

Common peptide pairings

Stacks to avoid or be cautious with

• AOD-9604 + stimulant fat burners (clenbuterol, DNP): unnecessary cardiac and metabolic risk
• AOD-9604 + high-dose hGH: defeats the purpose of using a non-IGF-1-raising fragment

Cycling

There is no consensus protocol because there is no strong evidence that AOD-9604 builds tolerance or requires washout for receptor recovery.

Common patterns

Most users will know within 8–12 weeks whether AOD-9604 is producing any noticeable effect in their context. If not, longer cycles are unlikely to change that.

Realistic Expectations

This section matters more than any other in this guide.

AOD-9604 is one of the most over-marketed peptides in the wellness space. The story is compelling: a precisely engineered fragment of growth hormone that targets fat without side effects, developed by real pharmaceutical scientists in real Phase III trials. That story is technically accurate. The trial outcomes are the part that gets quietly omitted.

What the evidence actually supports

• AOD-9604 is safe at studied doses
• AOD-9604 produces measurable lipolytic signaling in vitro and in rodents
• AOD-9604 produces modest, sometimes statistically insignificant fat loss in human obesity trials
• AOD-9604 is not an approved obesity drug anywhere in the world

What the evidence does not support

• "Dramatic" fat loss
• Body-recomposition results comparable to GLP-1s or full GH
• Spot reduction of fat
• Standalone use without diet and training

Who might still consider AOD-9604

• Users already optimized on diet and training who want to try a mild adjunct with a clean safety profile
• Users who cannot tolerate stimulant-based fat loss aids
• Users who are explicitly avoiding IGF-1 elevation (e.g., for personal or medical reasons)

If you are looking for a peptide that produces visible body composition changes on its own, AOD-9604 is almost certainly not it.

Frequently Asked Questions

Q: What's the actual difference between AOD-9604 and Fragment 176-191? A: AOD-9604 is the same hGH C-terminus region as Fragment 176-191, but with an added tyrosine residue and a disulfide bridge that improve stability. Mechanistically they are marketed similarly. Clinically, AOD-9604 has a real human trial record (with modest results), while Fragment 176-191 is largely preclinical.

Q: Will I see "photo results" like the ones in vendor marketing? A: Almost certainly not from AOD-9604 alone. Visible transformation photos typically reflect months of dieting and training, often combined with multiple compounds. AOD-9604 is, at best, a mild adjunct.

Q: Oral troche vs subcutaneous injection — which is better? A: Injection is more predictable. Troches and oral forms have uncertain bioavailability for this peptide, so doses are typically increased 2–4× to compensate. If a compounding pharmacy is your only legal access route, troches may be the practical choice.

Q: Is AOD-9604 banned by WADA? A: AOD-9604 falls under WADA's S2 category covering peptide hormones, growth factors, and related substances. Competitive athletes should assume it is prohibited in and out of competition.

Q: Can I stack AOD-9604 with semaglutide or tirzepatide? A: Some clinicians do combine them, with GLP-1 receptor agonists doing the heavy lifting on appetite and weight loss, and AOD-9604 acting as a minor adjunct. Discuss with the prescriber managing your GLP-1 — drug interactions are not the concern, but combining strategies should be intentional.

Q: Will AOD-9604 raise my IGF-1? A: Based on the available trial data, no. This is a key differentiator from full hGH and from secretagogues like CJC-1295/ipamorelin.

Q: Is AOD-9604 FDA-approved? A: No. The original obesity drug program was discontinued. It is available in the U.S. only through compounding pharmacies (typically as a sublingual troche) or sold as a research chemical. Status changes over time — verify current regulatory standing before sourcing.

Q: How do I know I'm actually getting AOD-9604 and not Fragment 176-191 or filler? A: Demand a third-party Certificate of Analysis from an independent lab (HPLC + mass spectrometry). Even then, supply integrity for niche fragments is imperfect. Stick to vendors with a long track record and consistent testing.

Related Content

• Fragment 176-191 Guide
• CJC-1295 Protocol
• Ipamorelin Protocol
• Tesamorelin Protocol
• GH Peptide Stacking Guide
• COA Reading Guide

Disclaimer: This content is for educational purposes only and is not medical advice. AOD-9604 is not FDA-approved for weight loss or any other indication. It is available in limited contexts via compounding pharmacies and is widely sold as a research chemical. Always consult a licensed healthcare provider before starting any peptide protocol, and verify the current regulatory status in your jurisdiction.

Source: https://peptides.nyc/learn/aod-9604-protocol